In this regard, knockdown of Sphingosine kinase 1 (SK1) was associated with downregulation of NSUN2 in breast and prostate cancer cells [123], suggesting that pharmacological inhibitors of SK1 could potentially benefit cancers with overexpressed NSUN2 [124]. The gene discussed is SPHK1; the disease is prostate carcinoma.